Filtered By:
Condition: Heart Failure
Procedure: Lung Transplant

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 76 results found since Jan 2013.

Medtronic touts stroke data for HeartWare LVAD
A retrospective analysis of two studies involved the HeartWare left-ventricular assist device Medtronic (NYSE:MDT) acquired in 2016 showed that managing blood pressure reduced the severity of strokes in patients implanted with the HVAD pump. The analysis, of “destination therapy” patients who are not candidates for a heart transplant, took data from the Endurance and Endurance Supplemental studies. Results were presented this week at the annual meeting of the International Society for Heart & Lung Transplantation in London, Medtronic said. The 465-patient Endurance Supplemental study compared 308 patients i...
Source: Mass Device - April 5, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Featured Abbott HeartWare International Inc. Medtronic stjudemedical Thoratec Corp. Source Type: news

ISHLT 2017: Medtronic HVAD trial misses primary endpoint, reports lowered stroke rates
Medtronic (NYSE:MDT) said today that results from the Endurance supplemental trial of its HVAD heart pump system did not meet its primary endpoint, but did report  lowered stroke rates compared to standard treatment. The trial aimed to evaluate the use of the HVAD system, which it picked up along with HeartWare last year, as a destination therapy for patients who require a left ventricular assist device and received improved blood pressure management, the Fridley, Minn.-based company said. Data from the study was presented at the 2017 International Society for Heart and Lung Transplantation Scientific Meeting in San Dieg...
Source: Mass Device - April 5, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Clinical Trials HeartWare International Inc. Medtronic Source Type: news

Blood pressure and stroke risk in left ventricular assist devices
Ischemic and hemorrhagic stroke are one of the most devastating outcomes arising from treatment of end-stage congestive heart failure with a left ventricular assist device (LVAD)1. Stroke after LVAD is associated with increased risk of mortality and is a leading cause of not qualifying for transplantation. The risk of stroke is one of many factors limiting more widespread adoption of this technology for end-stage heart failure. The risk factors for stroke in LVAD have been the subject of several studies, with recent infection2 and changes in anti-thrombotics being commonly found3.
Source: The Journal of Heart and Lung Transplantation - December 5, 2014 Category: Transplant Surgery Authors: Joshua Z. Willey Source Type: research

Carotid Artery Blood Flow and Its Association with Stroke during Left Ventricular Assist Device Support
Left ventricular assist device (LVAD) surgery is a life-prolonging therapy for advanced heart failure (HF). Despite many improvements over the years, LVADs continue to be associated with a high incidence of stroke and other vascular complications such as gastrointestinal bleeding (GIB). At present, the pathogenesis of these complications during LVAD support remains unclear. Abnormal structure and hemodynamics in large arteries are a potential contributor. We hypothesized that structural abnormalities and flow alterations will be significantly associated with stroke and a composite outcome of stroke, GIB, and death in HF pa...
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: M.E. Kiyatkin, A.M. Zuver, A. Gaudig, M. Tiburcio, B.J. McDonnell, M. Yuzefpolskaya, P.C. Colombo, E.J. St öhr, J.Z. Willey Tags: 401 Source Type: research

Different Risk Factors for Ischemic and Hemorrhagic Stroke on Continuous Flow Left Ventricular Assist Device Support
Patients with end-stage heart failure on left ventricular assist devices are predisposed to stroke. Preoperative factors associated with increased stroke risk are poorly understood.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: H.K. Lamba, M. Kim, L. Hart, B. Chou, C. Rao, S. Chatterjee, S. Sattee, F. Cheema, A. Civitello, R. Delgado, A. Nair, A. Shafii, G. Loor, T. Rosengart, O. Frazier, J. Morgan Tags: 402 Source Type: research

Effect of a Multifaceted Team Management Approach on Survival and Stroke Rates in Heartmate 2 Recipients
We report the effect of a comprehensive HM II management strategy on survival and stroke rates.
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: U. Jorde, N. Siddiqi, A. Luke, D.B. Sims, O. Saeed, S.R. Patel, S. Murthy, J. Shin, S. Watts, E. Borukhov, S. Madan, S. Thompson, R. Bello, S. Forest, S. Vukelic, C. Nucci, S. Rangasamy, D. Goldstein Source Type: research

Stroke and Survival Outcomes in Left Ventricular Device Patients
Left ventricular assist devices (LVADs) are artificial pumps used for hemodynamic support in patients with end stage heart failure. They can function effectively as a bridge to transplant as well as extend and improve the quality of life of patients. However, these patients are still at a higher risk of stroke, death, and other complications than the average population.
Source: The Journal of Heart and Lung Transplantation - April 1, 2023 Category: Transplant Surgery Authors: N. Berg, C. Shah, M. Guglin, H. Ferguson Tags: (759) Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Carotid-bulb thrombus and continuous-flow left ventricular assist devices: A novel observation
The continuous-flow left ventricular assist device (LVAD) has emerged as a clinically important treatment strategy for patients with advanced-stage heart failure. However, LVADs are not without associated neurologic complications, including stroke. In one review, the incidence of stroke (both ischemic and hemorrhagic) with the HeartMate II (HM II; Thoratec, Pleasanton, CA) ranged from 2% to 18%. In another recent single-center study, the incidence was 10%. In that study, previous stroke, persistent malnutrition and inflammation, severity of heart failure and post-LVAD infections were associated with neurologic complications.
Source: The Journal of Heart and Lung Transplantation - October 28, 2013 Category: Transplant Surgery Authors: John T. Reul, George J. Reul, O.H. Frazier Tags: Research Correspondence Source Type: research

Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.
Authors: Robson A, Sturman J, Williamson P, Conboy P, Penney S, Wood H Abstract This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the pre-treatment clinical assessment of patients presenting with head and neck cancer. Recommendations • Comorbidity data should be collected as it is important in the analysis of survival, quality of life and functional outcomes after treatment as well as for comparing results of different treatment regimens and different centres. (R) • Patients with hypertens...
Source: Journal of Laryngology and Otology - November 15, 2016 Category: ENT & OMF Tags: J Laryngol Otol Source Type: research

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

The Impact of Statin Therapy on Neurological Events Following Left Ventricular Assist System Implantation in Advanced Heart Failure
Stroke is a leading cause of disability and death in advanced heart failure patients supported with continuous-flow left ventricular assist systems (CF-LVAS). Statins (HMG-CoA Reductase Inhibitors) reduce the risk of major cardiovascular and neurological events, such as stroke, but their impact has not been evaluated in patients implanted with CF-LVAS. We sought to explore the association between use of statin therapy and subsequent occurrence of neurological events, particularly stroke, following CF-LVAS implantation.
Source: The Journal of Heart and Lung Transplantation - March 3, 2020 Category: Transplant Surgery Authors: Jefferson L. Vieira, Michael Pfeffer, Brian L. Claggett, Garrick C. Stewart, Michael M. Givertz, Lara Coakley, Hari R. Mallidi, Mandeep R. Mehra Tags: Original Clinical Science Source Type: research

What is the best approach in a patient with a failed aortic bioprosthetic valve: transcatheter aortic valve replacement or redo aortic valve replacement?
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether transcatheter aortic valve-in-valve replacement (viv-TAVR) or redo aortic valve replacement (rAVR) is the best strategy in a patient with a degenerative bioprosthetic aortic valve. Altogether, 162 papers were found using the reported search, of which 12 represented the best evidence to answer the question. The authors, journal, date, country of publication, patient group, study type, outcomes and results of papers are tabulated. The results of the studies provided interesting results. All the studies ...
Source: Interactive CardioVascular and Thoracic Surgery - May 28, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Tourmousoglou, C., Rao, V., Lalos, S., Dougenis, D. Tags: Lung - cancer, Trachea and bronchi, Congestive Heart Failure, Transplantation - heart, Valve disease, Vascular malformations Adult Cardiac Source Type: research

ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders
This invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA, to be followed by a Phase I clinical trial planned for 2017. Disorders amenable to treatment with the peptides include hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, HDL deficiency, hypertriglyceridemia, apoA-I deficiency, acute coronary syndrome, angina pectoris, ...
Source: NIH OTT Licensing Opportunities - February 1, 2008 Category: Research Authors: ajoyprabhu3 Source Type: research

4D Flow MRI in 3D Printed Models of Aorta Grafted With a Ventricular Assist Device Allows Detailed Embolic Trajectory Analysis
Embolic stroke remains an important source of morbidity and mortality in heart failure patients treated with Ventricular Assist Devices (VADs). Decreasing the probability of cranial versus descending aortic embolic trajectory by optimizing the VAD outflow graft position and terminal curvature angle could reduce embolic stroke risk. The goal of this study is to investigate particle trajectories released by a VAD into the aorta, and the effect changes in outflow graft insertion site and terminal curve have on those trajectories.
Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: O. Amili, F. Coletti, R. MacIver Source Type: research